Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil

Detalhes bibliográficos
Ano de defesa: 2021
Autor(a) principal: Fernanda Waechter
Orientador(a): Elizabeth de Souza Nascimento
Banca de defesa: Silvia Berlanga de Moraes Barros, Joel Paul Bercu, Maria Augusta Carvalho Rodrigues
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: eng
Instituição de defesa: Universidade de São Paulo
Programa de Pós-Graduação: Farmácia (Análise Clínicas)
Departamento: Não Informado pela instituição
País: BR
Link de acesso: https://doi.org/10.11606/D.9.2021.tde-05082021-111631
Resumo: The presence of impurities in drug products has been controlled according to international guidelines in Brazil and the entire world. Impurities with mutagenic potential tend to show a greater toxicity and consequently need to be controlled to lower limits than the other regular impurities. The international guideline for control of mutagenic impurities (ICH M7) is not applicable for drug products which are already approved. However, some mutagenic impurities have recently been found above the permitted limits in valsartan, losartan, ranitidine, and other drug products which were already approved by regulatory agencies. The objective of this project is to identify the possible mutagenic impurities in anti-hypertensive drugs approved in Brazil and perform the risk assessment proposing control strategies for such impurities. The possible impurities in each drug substance were identified based on the drug master file, a document where the manufacturer describes the manufacturing process and potential impurities of the drug substance. For the mutagenicity prediction of the impurities, in silico systems were used, and in one inconclusive case the Ames test was performed. For evaluation of the levels of the impurities in the drug substance, in silico tools such as the purge factor approach, as well as validated analytical procedures were used. A total of 15 drug substances was evaluated, and 262 impurities were identified. The results show that 22% of these impurities are potentially mutagenic, however all of them, except for impurities described in a pharmacopoeial monograph, are below the acceptable limits. This suggests that although mutagenic impurities are present at low levels in drug substances, the current manufacturing processes seem to be adequate to keep the negligible risk. Nonetheless, there is an evident need to establish control strategies which ensure the levels of mutagenic impurities are below the acceptable limits throughout all manufactured batches. Moreover, it is recommended to evaluate the potential mutagenicity of impurities described in pharmacopoeial monographs, understanding whether there is a need to tighten limits.
id USP_a1126c9805ca0b136ae4e6782cfbecf0
oai_identifier_str oai:teses.usp.br:tde-05082021-111631
network_acronym_str USP
network_name_str Biblioteca Digital de Teses e Dissertações da USP
repository_id_str
spelling info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesis Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil Avaliação do risco de impurezas potencialmente mutagênicas em medicamentos anti-hipertensivos registrados no Brasil 2021-04-19Elizabeth de Souza NascimentoAntonio Anáx Falcão de OliveiraSilvia Berlanga de Moraes BarrosJoel Paul BercuMaria Augusta Carvalho RodriguesFernanda WaechterUniversidade de São PauloFarmácia (Análise Clínicas)USPBR Ensaios toxicológicos in silico ICH M7 ICH M7 Impurezas farmacêuticas in silico toxicological assays Mutagenicidade Mutagenicity Pharmaceutical impurities The presence of impurities in drug products has been controlled according to international guidelines in Brazil and the entire world. Impurities with mutagenic potential tend to show a greater toxicity and consequently need to be controlled to lower limits than the other regular impurities. The international guideline for control of mutagenic impurities (ICH M7) is not applicable for drug products which are already approved. However, some mutagenic impurities have recently been found above the permitted limits in valsartan, losartan, ranitidine, and other drug products which were already approved by regulatory agencies. The objective of this project is to identify the possible mutagenic impurities in anti-hypertensive drugs approved in Brazil and perform the risk assessment proposing control strategies for such impurities. The possible impurities in each drug substance were identified based on the drug master file, a document where the manufacturer describes the manufacturing process and potential impurities of the drug substance. For the mutagenicity prediction of the impurities, in silico systems were used, and in one inconclusive case the Ames test was performed. For evaluation of the levels of the impurities in the drug substance, in silico tools such as the purge factor approach, as well as validated analytical procedures were used. A total of 15 drug substances was evaluated, and 262 impurities were identified. The results show that 22% of these impurities are potentially mutagenic, however all of them, except for impurities described in a pharmacopoeial monograph, are below the acceptable limits. This suggests that although mutagenic impurities are present at low levels in drug substances, the current manufacturing processes seem to be adequate to keep the negligible risk. Nonetheless, there is an evident need to establish control strategies which ensure the levels of mutagenic impurities are below the acceptable limits throughout all manufactured batches. Moreover, it is recommended to evaluate the potential mutagenicity of impurities described in pharmacopoeial monographs, understanding whether there is a need to tighten limits. A presença de impurezas em medicamentos tem sido controlada conforme guias internacionais no Brasil e ao redor do mundo. Impurezas com potencial mutagênico tendem a apresentar uma maior toxicidade e consequentemente limites mais baixos do que os aplicados às demais impurezas. O guia internacional para controle de impurezas mutagênicas (ICH M7) não é aplicável a medicamentos já aprovados. Porém, recentemente algumas impurezas mutagênicas foram encontradas acima dos limites permitidos na valsartana, losartana, ranitidina, e outros medicamentos que já eram aprovados por agências reguladoras. O objetivo desse trabalho é identificar as possíveis impurezas mutagênicas em medicamentos anti-hipertensivos aprovados no Brasil e realizar a avaliação do risco propondo estratégias de controle para tais impurezas. As possíveis impurezas em cada fármaco foram identificadas com base no arquivo mestre do fármaco, um documento no qual o fabricante descreve o processo de fabricação e as impurezas potenciais do fármaco. Visando prever a mutagenicidade das impurezas, sistemas in silico foram utilizados, e para um caso inconclusivo o teste de Ames foi realizado. Para avaliar os níveis das impurezas no fármaco, foram utilizadas tanto ferramentas in silico (fator de purga), como métodos analíticos validados. Um total de 15 fármacos foi avaliado, e 262 impurezas foram identificadas. Os resultados mostram que 22% dessas impurezas são potencialmente mutagênicas, porém, com exceção das impurezas farmacopeicas, em todos os casos os níveis encontrados são inferiores aos limites aceitáveis. Isso sugere que apesar de haver a presença de impurezas mutagênicas em baixos níveis nos fármacos, os processos de fabricação atualmente utilizados parecem ser adequados para manter o risco negligenciável. É necessário estabelecer estratégias de controle que garantam que os níveis das impurezas mutagênicas permanecerão abaixo dos limites aceitáveis em todos os lotes produzidos. Além disso, recomenda-se a avaliação do potencial mutagênico de impurezas descritas em monografias farmacopeicas, a fim de definir se existe a necessidade de restrição dos limites. https://doi.org/10.11606/D.9.2021.tde-05082021-111631info:eu-repo/semantics/openAccessengreponame:Biblioteca Digital de Teses e Dissertações da USPinstname:Universidade de São Paulo (USP)instacron:USP2023-12-21T18:16:29Zoai:teses.usp.br:tde-05082021-111631Biblioteca Digital de Teses e Dissertaçõeshttp://www.teses.usp.br/PUBhttp://www.teses.usp.br/cgi-bin/mtd2br.plvirginia@if.usp.br|| atendimento@aguia.usp.br||virginia@if.usp.bropendoar:27212023-08-05T12:58:20Biblioteca Digital de Teses e Dissertações da USP - Universidade de São Paulo (USP)false
dc.title.en.fl_str_mv Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
dc.title.alternative.pt.fl_str_mv Avaliação do risco de impurezas potencialmente mutagênicas em medicamentos anti-hipertensivos registrados no Brasil
title Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
spellingShingle Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
Fernanda Waechter
title_short Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
title_full Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
title_fullStr Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
title_full_unstemmed Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
title_sort Risk assessment of potentially mutagenic impurities in anti-hypertensive drug products approved in Brazil
author Fernanda Waechter
author_facet Fernanda Waechter
author_role author
dc.contributor.advisor1.fl_str_mv Elizabeth de Souza Nascimento
dc.contributor.advisor-co1.fl_str_mv Antonio Anáx Falcão de Oliveira
dc.contributor.referee1.fl_str_mv Silvia Berlanga de Moraes Barros
dc.contributor.referee2.fl_str_mv Joel Paul Bercu
dc.contributor.referee3.fl_str_mv Maria Augusta Carvalho Rodrigues
dc.contributor.author.fl_str_mv Fernanda Waechter
contributor_str_mv Elizabeth de Souza Nascimento
Antonio Anáx Falcão de Oliveira
Silvia Berlanga de Moraes Barros
Joel Paul Bercu
Maria Augusta Carvalho Rodrigues
description The presence of impurities in drug products has been controlled according to international guidelines in Brazil and the entire world. Impurities with mutagenic potential tend to show a greater toxicity and consequently need to be controlled to lower limits than the other regular impurities. The international guideline for control of mutagenic impurities (ICH M7) is not applicable for drug products which are already approved. However, some mutagenic impurities have recently been found above the permitted limits in valsartan, losartan, ranitidine, and other drug products which were already approved by regulatory agencies. The objective of this project is to identify the possible mutagenic impurities in anti-hypertensive drugs approved in Brazil and perform the risk assessment proposing control strategies for such impurities. The possible impurities in each drug substance were identified based on the drug master file, a document where the manufacturer describes the manufacturing process and potential impurities of the drug substance. For the mutagenicity prediction of the impurities, in silico systems were used, and in one inconclusive case the Ames test was performed. For evaluation of the levels of the impurities in the drug substance, in silico tools such as the purge factor approach, as well as validated analytical procedures were used. A total of 15 drug substances was evaluated, and 262 impurities were identified. The results show that 22% of these impurities are potentially mutagenic, however all of them, except for impurities described in a pharmacopoeial monograph, are below the acceptable limits. This suggests that although mutagenic impurities are present at low levels in drug substances, the current manufacturing processes seem to be adequate to keep the negligible risk. Nonetheless, there is an evident need to establish control strategies which ensure the levels of mutagenic impurities are below the acceptable limits throughout all manufactured batches. Moreover, it is recommended to evaluate the potential mutagenicity of impurities described in pharmacopoeial monographs, understanding whether there is a need to tighten limits.
publishDate 2021
dc.date.issued.fl_str_mv 2021-04-19
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.11606/D.9.2021.tde-05082021-111631
url https://doi.org/10.11606/D.9.2021.tde-05082021-111631
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade de São Paulo
dc.publisher.program.fl_str_mv Farmácia (Análise Clínicas)
dc.publisher.initials.fl_str_mv USP
dc.publisher.country.fl_str_mv BR
publisher.none.fl_str_mv Universidade de São Paulo
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da USP
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Biblioteca Digital de Teses e Dissertações da USP
collection Biblioteca Digital de Teses e Dissertações da USP
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da USP - Universidade de São Paulo (USP)
repository.mail.fl_str_mv virginia@if.usp.br|| atendimento@aguia.usp.br||virginia@if.usp.br
_version_ 1786376583225802752